SUBSCRIBE
SUBSCRIBE

Beam Therapeutics

AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2024 Best Places to Work
  • 2022 Best Places to Work
  • NextGen Class of 2019
NEWS
Business
BioSpace Movers and Shakers, May 17
Biopharma companies add new leaders to executive roles and boards of directors.
May 16, 2019
 · 
5 min read
 · 
Alex Keown
Business
Beam Therapeutics Closes Series B Financing Worth $135 Million
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
March 6, 2019
 · 
3 min read
 · 
Mark Terry
Business
Top 20 Life Science Startups to Watch in 2019
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
November 6, 2018
 · 
12 min read
 · 
Mark Terry
Load More
JOBS
IN THE PRESS
Press Releases
Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac
June 11, 2025
 · 
6 min read
Business
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
 · 
10 min read
Business
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
June 30, 2021
 · 
7 min read
Genetown
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies
June 15, 2020
 · 
10 min read
Deals
Beam Therapeutics Announces Closing of Initial Public Offering
February 11, 2020
 · 
2 min read
Deals
Beam Therapeutics Announces Pricing of Initial Public Offering at $17.00 per share
February 11, 2020
 · 
2 min read
Genetown
Beam Therapeutics Announces Multiple Scientific Advances in its Base Editing Technology Platforms
February 11, 2020
 · 
5 min read
Deals
Beam Therapeutics Announces Pricing of Initial Public Offering at $17.00 per share.
February 5, 2020
 · 
2 min read
Business
Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific Officer
January 24, 2020
 · 
2 min read
Drug Development
Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019
December 8, 2019
 · 
3 min read
Load More